ProductLife Group (PLG) has announced a strategic acquisition of IntiQuan, a Swiss pharmacometrics specialist, marking a significant expansion of its drug development capabilities. The acquisition strengthens PLG's position in providing sophisticated modeling and simulation services to biopharmaceutical companies.
Advanced Modeling Capabilities
IntiQuan, established in Switzerland in 2015, brings expertise in pharmacometric and statistical modeling that enables more precise drug development processes. The company's mathematical modeling and simulation capabilities help predict clinical trial outcomes, offering pharmaceutical companies valuable insights for decision-making.
The integration adds critical services to PLG's portfolio, including:
- Population pharmacokinetics
- Pharmacokinetics/pharmacodynamics analysis
- Strategic consulting
- Biosimulation services
Impact on Drug Development
Xavier Duburcq, CEO of ProductLife Group, emphasized the strategic value of the acquisition: "Pharmacometrics and model-informed drug development offer regulatory grade insights that can impact key decision-making and accelerate clinical development, even eliminating the need for certain trials, in some cases."
The enhanced capabilities are expected to:
- Reduce development risks
- Lower research costs
- Shorten development timelines
- Improve patient safety through advanced analyses
Strategic Growth and Market Position
The acquisition represents a crucial step in PLG's strategy to build an integrated global platform for drug development services. With planned expansions in both US and European markets, the company is positioning itself as a leading provider of comprehensive drug development solutions.
Dr. Henning Schmidt, IntiQuan's founder, highlighted the significance of the merger: "Joining forces with PLG is a pivotal moment for IntiQuan. Our teams support IntiQuan's clients bringing breakthrough medicines to patients and reducing both time to market and the cost of research and development through our combined solutions."
